Andrew S. Fein Analyst PerformanceMD/Senior Analyst at HC WainwrightAndrew S. Fein is a stock analyst at HC Wainwright in the medical sector, covering 28 publicly traded companies. Over the past year, Andrew S. Fein has issued 58 stock ratings, including buy and hold recommendations. While full access to Andrew S. Fein's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrew S. Fein's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings58 Last 0 YearsBuy Recommendations91.38% 53 Buy RatingsCompanies Covered28 Unique Companies Ratings Distribution58RatingsDistribution of strong buy, buy, hold, and sell ratings by Andrew S. Fein.RatingPercentageCount Strong Buy0.0%0 ratings Buy91.4%53 ratings Hold8.6%5 ratings Sell0.0%0 ratingsOut of 58 total stock ratings issued by Andrew S. Fein at HC Wainwright, the majority (91.4%) have been Buy recommendations, followed by 8.6% Hold.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ28 companiesAndrew S. Fein, an analyst at HC Wainwright, currently covers 28 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical28 companies100.0%Andrew S. Fein of HC Wainwright specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE20 companies71.4%MED - DRUGS8 companies28.6% About Andrew S. FeinMr. Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart. Mr. Fein has received numerous honorable mentions from the Institutional Investor All-America Research poll. Mr. Fein’s educational background includes a Bachelor of Arts degree from Yale University.Follow on LinkedIn Andrew S. Fein's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsWVEWAVE Life Sciences5/19/2026Lower Price Target$6.40$13.00Buy$0.0000.00% ROIMTVAMetaVia5/18/2026Reiterated Rating$1.11$20.00Buy$0.0000.00% ROILQDALiquidia5/12/2026Boost Price Target$53.30$67.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals5/6/2026Reiterated Rating$502.47$620.00Buy$0.0000.00% ROIKALVKalVista Pharmaceuticals5/1/2026Downgrade$26.66$27.00Neutral$0.0000.00% ROIAURAAura Biosciences4/29/2026Boost Price Target$6.96$24.00Buy$0.0000.00% ROITARAProtara Therapeutics4/29/2026Boost Price Target$5.06$27.00Buy$0.0000.00% ROIWVEWAVE Life Sciences4/14/2026Lower Price Target$7.26$18.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences4/7/2026Boost Price Target$132.48$215.00Buy$0.0000.00% ROIBIIBBiogen4/2/2026Boost Price Target$183.78$237.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. UTHRUnited Therapeutics3/31/2026Boost Price Target$583.78$660.00Buy$0.0000.00% ROIMTVAMetaVia3/27/2026Lower Price Target$1.27$20.00Buy$0.0000.00% ROIDNLIDenali Therapeutics3/26/2026Boost Price Target$22.47$42.00Buy$0.0000.00% ROIINSMInsmed3/26/2026Boost Price Target$149.18$245.00Buy$0.0000.00% ROIAMLXAmylyx Pharmaceuticals3/25/2026Reiterated Rating$13.66$34.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics3/24/2026Boost Price Target$115.73$270.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals3/10/2026Boost Price Target$460.87$641.00Buy$0.0000.00% ROILQDALiquidia3/6/2026Boost Price Target$34.52$55.00Buy$0.0000.00% ROIAMLXAmylyx Pharmaceuticals3/4/2026Boost Price Target$14.67$34.00Buy$0.0000.00% ROIWVEWAVE Life Sciences3/2/2026Reiterated Rating$13.93$30.00Buy$0.0000.00% ROIUTHRUnited Therapeutics2/26/2026Boost Price Target$503.28$600.00Buy$0.0000.00% ROIINSMInsmed2/23/2026Reiterated Rating$164.91$230.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals2/13/2026Boost Price Target$465.02$518.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences2/12/2026Lower Price Target$137.44$192.00Buy$0.0000.00% ROIAMLXAmylyx Pharmaceuticals2/10/2026Boost Price Target$14.22$28.00Buy$0.0000.00% ROIBIIBBiogen2/9/2026Boost Price Target$201.18$228.00Buy$0.0000.00% ROIMTVAMetaVia1/6/2026Boost Price Target$8.21$40.00Buy$0.0000.00% ROIINSMInsmed12/18/2025Lower Price Target$165.88$230.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences12/17/2025Boost Price Target$148.74$198.00Buy$0.0000.00% ROIBCRXBioCryst Pharmaceuticals12/15/2025Boost Price Target$7.58$32.00Buy$0.0000.00% ROIKMDAKamada12/9/2025Boost Price Target$6.73$13.00Buy$0.0000.00% ROIFULCFulcrum Therapeutics12/8/2025Boost Price Target$8.90$25.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/21/2025Boost Price Target$556.75$620.00Buy$0.0000.00% ROIARCTArcturus Therapeutics11/11/2025Lower Price Target$8.69$9.00Neutral$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/11/2025Boost Price Target$524.24$568.00Buy$0.0000.00% ROIPRTAProthena11/7/2025Boost Price Target$10.19$30.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics11/6/2025Boost Price Target$75.75$190.00Buy$0.0000.00% ROIDBVTDBV Technologies10/29/2025Reiterated Rating$14.55$20.00Buy$0.0000.00% ROIARCTArcturus Therapeutics10/24/2025Reiterated Rating$12.00$12.00Neutral$0.0000.00% ROIFULCFulcrum Therapeutics10/20/2025Reiterated Rating$8.99$12.00Buy$0.0000.00% ROIA letter from Shannon Stansberry (Ad)Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.Watch the full story and see the verified track record for yourselfPRTAProthena10/7/2025Boost Price Target$9.86$20.00Buy$0.0000.00% ROILQDALiquidia10/6/2025Reiterated Rating$22.43$35.00Buy$0.0000.00% ROIETNB89BIO9/19/2025Downgrade$14.96$14.50Neutral$0.0000.00% ROIKYMRKymera Therapeutics9/18/2025Boost Price Target$48.12$70.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals9/4/2025Initiated Coverage$7.44$7.44Neutral$0.0000.00% ROIMTVAMetaVia9/4/2025Initiated Coverage$7.36$132.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals9/4/2025Initiated Coverage$435.27$500.00Buy$0.0000.00% ROIARCTArcturus Therapeutics9/4/2025Initiated Coverage$17.19$60.00Buy$0.0000.00% ROIAKROAkero Therapeutics9/4/2025Initiated Coverage$45.62$72.00Buy$0.0000.00% ROIETNB89BIO9/4/2025Initiated Coverage$9.24$32.00Buy$0.0000.00% ROISVRASavara9/3/2025Boost Price Target$3.39$8.00Buy$0.0000.00% ROIWVEWAVE Life Sciences9/3/2025Reiterated Rating$7.55$22.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics8/15/2025Boost Price Target$46.10$75.00Buy$0.0000.00% ROISVRASavara8/15/2025Upgrade$3.01$5.00Buy$0.0000.00% ROIARVNArvinas8/7/2025Lower Price Target$6.11$18.00Buy$0.0000.00% ROIDAWNDay One Biopharmaceuticals8/6/2025Lower Price Target$6.88$25.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals8/5/2025Lower Price Target$472.27$478.00Buy$0.0000.00% ROIPRTAProthena8/5/2025Reiterated Rating$6.94$14.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
